한글목차

전 세계 인간 마이크로바이옴 유래 의약품 및 진단 시장 규모는 2025년 3억 9,340만 달러에서 2030년 말 12억 달러로 확대될 것으로 예상되며, 2025년부터 2030년까지 25.6%의 CAGR을 기록할 것으로 예측됩니다.

북미 시장 규모는 2025년 2억 2,570만 달러에서 2030년 말 5억 7,890만 달러로 확대될 것으로 예상되며, 같은 기간 CAGR은 20.7%로 추정됩니다.

유럽 시장 규모는 2025년 6,930만 달러에서 2030년 말 3억 590만 달러로 확대될 것으로 예상되며, 같은 기간 CAGR은 34.6%로 예측됩니다.

세계의 인간 마이크로바이옴 유래 의약품 및 진단 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법·규제 환경, 신기술 및 기술 개발 동향, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약
• 시장 역학
• 신기술
• 부문별 분석
• 지역 분석
• 결론

제2장 시장 개요

• 개요와 시장 정의
• 인간의 다양한 마이크로바이옴
• 마이크로바이옴과 인간 건강·질환의 관계
• 마이크로바이옴 연구를 지지하는 기술
• 배양 및 재배 기술
• 마이크로바이옴 치료제 개발 전략
• 첨가형 마이크로바이옴 요법
• 조절형 마이크로바이옴 요법
• 거시경제 요인 분석
• 지정학적 요인
• 인플레이션 및 환율 변동
• Porter's Five Forces 분석

제3장 시장 역학

• 요약
• 시장 성장 촉진요인
• 마이크로바이옴과 질환의 상관에 관한 증거 증가
• 질병 예방과 모니터링을 위한 마이크로바이옴에 기반한 진단
• 시장 성장 억제요인
• 임상시험 설계의 과제
• 확립된 규제 프레임워크의 결여
• 마이크로바이옴 치료의 고비용
• 시장 기회
• 소비자용 마이크로바이옴 검사 보급
• 폐와 피부의 마이크로바이옴에 대한 약제와 진단

제4장 규제 상황

• 규제
• 북미
• 유럽
• 아시아태평양

제5장 신기술

• 요약
• 신기술
• 미생물 생태계 요법
• 메타전사체 시퀀싱
• 유전자 변형 마이크로바이옴 치료제
• 마이크로바이옴 유래 의약품과의 병용요법 및 보조요법
• 신규 전임상 모델

제6장 시장 세분화 분석

• 세분화 내역
• 시장 분석 : 유형별
• 마이크로바이옴 기반 의약품
• 시장 분석 : 용도별
• 감염증
• 소화기질환
• 대사장애
• 암
• 기타
• 시장 분석 : 최종사용자별
• 병원·진료소
• 연구기관
• 제약회사
• 지역적 내역
• 시장 분석 : 지역별
• 북미
• 유럽
• 아시아태평양
• 남미
• 중동 및 아프리카

제7장 경쟁 정보

• 요약
• 기업 점유율 분석
• 경쟁 분석
• 벤처 자금 조달과 투자 상황
  • 최근 동향

제8장 인간 마이크로바이옴에 유래 의약품 및 진단 산업의 지속가능성 : ESG 관점

• ESG : 소개
• ESG 리스크 평가
• 결론

제9장 부록

• 조사 방법
• 정보 출처
• 약어
• 기업 개요
• BIOMEBANK
• ENTEROBIOTIX LTD.
• ENTEROME
• FERRING
• GENETIC ANALYSIS
• ILLUMINA INC.
• MICROBIOME INSIGHTS
• MICROBIOTICA
• NESTLE HEALTH SCIENCE
• OXFORD NANOPORE TECHNOLOGIES PLC
• PACBIO
• SFA THERAPEUTICS INC.
• THERMO FISHER SCIENTIFIC INC.
• VEDANTA BIOSCIENCES INC.

영문목차

The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

The North American market for human microbiome-based drugs and diagnostics is expected to grow from $225.7 million in 2025 to reach $578.9 million by the end of 2030, at a CAGR of 20.7% from 2025 through 2030.

The European market for human microbiome-based drugs and diagnostics is expected to grow from $69.3 million in 2025 to reach $305.9 million by the end of 2030, at a CAGR of 34.6% from 2025 through 2030.

Report Scope

The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.

Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.

Report Includes

• 55 data tables and 51 additional tables
• Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region
• Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
• Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments
• An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
• An analysis of the key patent grants and recently published patents
• Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook
• Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics
• Emerging Technologies
• Analysis by Segment
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Different Microbiomes in Humans
• Microbiome, Human Health and Disease
• Technologies Aiding Microbiome Research
• Culturing and Cultivation
• Strategies for the Development of Microbiome Therapeutics
• Additive Microbiome Therapy
• Modulatory Microbiome Therapy
• Analysis of Macroeconomic Factors
• Geopolitical Factors
• Inflation and Currency Exchange Fluctuations
• Porter's Five Forces Analysis

Chapter 3 Market Dynamics

• Takeaways
• Market Drivers
• Growing Evidence of Microbiome-disease Correlation
• Microbiome-based Diagnostics for Disease Prevention and Monitoring
• Market Restraints
• Challenges in Clinical Trial Design
• Lack of Established Regulatory Frameworks
• High Costs of Microbiome Therapeutics
• Market Opportunities
• Direct-to-Consumer Microbiome Testing
• Drugs and Diagnostics for Lung and Skin Microbiomes

Chapter 4 Regulatory Landscape

• Regulatory Aspects
• North America
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies

• Takeaways
• Emerging Technologies
• Microbial Ecosystem Therapeutics
• Metatranscriptome Sequencing
• Genetically Modified Microbiome Therapeutics
• Combination and Adjuvant Therapies with Microbiome-based Drugs
• Novel Preclinical Models

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Type
• Microbiome-based Drugs
• Market Analysis by Application
• Infectious Diseases
• GI Disorders
• Metabolic Disorders
• Cancer
• Other Diseases
• Market Analysis by End User
• Hospitals and Clinics
• Research Institutions
• Pharmaceutical Companies
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Takeaways
• Company Share Analysis
• Competitive Analysis
• Venture Funding and Investment Landscape
• Recent Developments

Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective

• Introduction to ESG
• ESG Risk Ratings
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• BIOMEBANK
• ENTEROBIOTIX LTD.
• ENTEROME
• FERRING
• GENETIC ANALYSIS
• ILLUMINA INC.
• MICROBIOME INSIGHTS
• MICROBIOTICA
• NESTLE HEALTH SCIENCE
• OXFORD NANOPORE TECHNOLOGIES PLC
• PACBIO
• SFA THERAPEUTICS INC.
• THERMO FISHER SCIENTIFIC INC.
• VEDANTA BIOSCIENCES INC.
• Emerging Start-ups/Market Disruptors